A study, conducted by The Institute of Cancer Research, London (ICR) and Paris-based cancer research institute Gustave Roussy, identified that drugs known as PARP inhibitors kill cancer cells with a particular defect in the PBRM1 gene.
Claritas Pharmaceuticals and CMAX Clinical Research have signed an agreement to conduct a Phase 1 clinical study of R-107.
Antengene has announced that China’s National Medical Products Administration (NMPA) has given approval to investigational new drug (IND) application for Phase I clinical trials of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
A study led by the University of California, Los Angeles (UCLA) has identified a compound, berzosertib, which showed potential in treating SARS-CoV-2 virus which causes Covid-19.
The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government.
A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.
GlaxoSmithKline has signed an agreement with Vir Biotechnology to expand their Covid-19 collaboration to advance new therapeutics for influenza and other respiratory viruses.
Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19 vaccine candidate.
The University of Oxford, along with three partner sites in the UK, has commenced the first trial to evaluate the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to moderate Covid-19 patients.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.